Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiopharmaceuticals and Zoledronic Acid for Bone Metastases
NCT00365105Phase 3Completed
- Sponsor
- NRG Oncology
- Start
- Jul 2006
- Primary completion
- Jan 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of strontium-89 and samarium-153 in bone metastases (2 arms), sponsored by NRG Oncology. Primary endpoint: Time to Development of a Malignant Skeletal-related Events up to 80.1 months. Started Jul 2006; status: completed.
02
Drugs
strontium-89samarium-153
03
Conditions
bone metastases
Beyond the preview
Go deeper on NCT00365105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00365105.